XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Advanced Solid Tumour Trials

A list of our early phase Advanced solid tumour & basket study trials which are open to recruitment at University College London Hospitals

To find more information on UCLH CRF Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

 

GO42144

A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies

Local Project Reference:140092
Principal Investigator:Dr. Martin Forster
Drug Class/ Treatment:AZD7648 (KRAS G12C Inhibito)
Patient Population:Advanced or Metastatic Solid Tumours with KRAS G12c Mutation
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

STARPHARMA CTX

A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours.

Local Project Reference:18/0016
Principal Investigator:Dr. Martin Forster
Drug Class/ Treatment:CTX-SPL9111 (Drug-Dendrimer Conjugate)
Patient Population:Advanced Solid Tumours
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

STARPHARMA DTX

A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC).

Local Project Reference:17/0585
Principal Investigator:Dr. Martin Forster
Drug Class/ Treatment:DTX-SPL8783 - Drug-Dendrimer Conjugate (Tubulin Polymerase Inhibitor)
Patient Population:Advanced Solid Tumours or Non-Small Cell Lung Cancer (NSCLC)
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

IMC-F106C-101

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

Local Project Reference:130728
Principal Investigator:Dr. Heather Shaw
Drug Class/ Treatment:IMC-F106C (Bispecific Antibody against HLA-A*02:01)
Patient Population:HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

GARNET

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Local Project Reference:16/0355
Principal Investigator:Dr. Rowan Miller
Drug Class/ Treatment:

TSR-042 (Anti PD-L1 Monoclonal Antibody)

Patient Population:

Advanced Solid Tumours

Part 2B: Cohort F - Patients with Recurrent or Advanced Non-endometrial dMMR/MSI-H Solid Tumours or POLE-Mut Cancers

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

AZD6738 in Combination With Other Agents in Solid Malignancies (D5330C00004)

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Local Project Reference:18/0067
Principal Investigator:Dr. Rowan Miller
Drug Class/ Treatment:

AZD6738 (Ceralasertib) - ATR Kinase Inhibitor + Olaparib

Patient Population:Part 5B: Patients with BRCA mutations or mutations in RAD51C or D (either germline or somatic) or HRD-positive status (Myriad GIS at or greater than 42 and FMI gLOH at or greater than 16) Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer according to local testing.
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

NX-1607-101

A Phase 1a Dose Escalation Safety and Tolerability Study of NX-1607 a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor in Adults with Advanced Malignancies with Phase 1b Expansion in Select Tumor Types:  A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

Local Project Reference:140364
Principal Investigator:Prof. Daniel Hochhauser
Drug Class/ Treatment:NX-1607 - CBL-B Inhibitor
Patient Population:Advanced Malignancies
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

TAPISTRY (BO41932)

TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL

Local Project Reference:138000
Principal Investigator:Dr. Martin Forster
Drug Class/ Treatment:Cohort C: Alectinib - ALK Inhibitor
Cohort H: Inavolisib (GDC-0077) - PI3K Inhibitor
Patient Population:Solid Tumours:
Cohort C - ALK Fusion-Positive Tumours
Cohort F - PIK3CA Multiple Mutant Positive Tumours
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

MODI-1-001

Modi-1 in Patients with Breast, Head & Neck, Ovarian or Renal Cancer:  A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer

Local Project Reference:142749
Principal Investigator:Dr. Rowan Miller
Drug Class/ Treatment:Modi-1 - Novel Cancer Vaccine
Patient Population:

Advanced Solid Tumours

  • Advanced Triple Negative Breast Cancer.
  • HPV-Negative Squamous Cell Carcinoma of the Head & Neck (oral cavity, oropharynx, hypopharynx, or larynx).
  • High Grade Serous Ovarian Carcinoma (including fallopian tube and primary peritoneal cancers).
  • Renal Cell Carcinoma.
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

 

ROLo

ROLo: Phase II study of ROS1 targeting with crizotinib in advanced E-cadherin negative, ER positive lobular breast cancer or diffuse gastric cancer

Local Project Reference:18/0518
Principal Investigator:Dr. Rebecca Roylance
Drug Class/ Treatment:Crizotinib (ROS1 Inhibitor) + Fulvestrant (Hormone Injections)
Patient Population:
  • Advanced E-Cadherin Negative ER Positive Lobular Breast Cancer
  • Diffuse Gastric Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

GSK SCOOP

A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSEESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS

Local Project Reference:140376
Principal Investigator:Dr. Sandra Strauss
Drug Class/ Treatment:Niraparib (PARP Inhibitor) + Dostarlimab (PDL1 Blocking Monoclonal Antibody)
Patient Population:

Recurrent or Refractory Solid Tumours

Paediatrics and TYA - ≥6 Months to <18 Years

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

 

Trials on-hold to recruitment

OVM-200-100

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine:  A Phase 1, Multicenter, Open-label, Nonrandomized, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer

Local Project Reference:

138608

Principal Investigator:Dr. Martin Forster
Drug Class/ Treatment:OVM-200 (Cancer Vaccine)
Patient Population:

Locally Advanced or Metastatic:

  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Prostate Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)